Influenza vaccination in 29 countries - An update to 1997
Influenza vaccination in 29 countries - An update to 1997
复制标题
DOI：
10.2165/00019053-199916001-00007
复制
发表时间：
1999-01-01
影响因子：
4.4
通讯作者：
Fedson, DS
中科院分区：
文献类型：
--
作者：
Ambrosch, F;Fedson, DS
目的：本报告更新1996年和1997年我们的2个早期报告中使用的流感疫苗在各个countries.Methods：方法获得信息的流感疫苗使用从1980年至1995年在每个国家在我们早期的报告中描述。目前的报告包括29个国家的数据。结果：在西欧的16个国家中，疫苗的使用大幅增加，在荷兰，芬兰（1996年）和爱尔兰（1997年）。在其余13个国家，疫苗使用有所增加或保持不变。在美国，疫苗使用在整个20世纪90年代稳步增加，1997年达到每1000人281剂的水平。在新西兰，1997年有大幅度增加，而在加拿大、澳大利亚和韩国，疫苗的使用相对保持不变。在日本和新加坡，很少或根本没有使用流感疫苗。1997年，6个中欧国家使用了少量的流感疫苗。在所有29个国家中，1997年，除3个国家（英国、爱尔兰和丹麦）外，所有国家都有基于年龄的流感疫苗接种建议。1998年，英国和丹麦分别建议年龄大于或等于75岁和大于或等于65岁的人接种疫苗。爱尔兰正在考虑一项基于年龄的建议。许多国家通过国家或社会医疗保险为流感疫苗接种提供报销，至少对某些推荐人群提供报销。然而，几乎在所有国家，许多人自己支付疫苗接种费用。不同国家的疫苗使用水平与人均医疗支出无关。相反，他们反映了不同程度的认识流感作为一种重要的疾病和疫苗接种的有效性，在其prevent.Conclusions：流感疫苗接种继续增加或已稳定在大多数发达国家，疫苗也正在使用在几个发展中国家。然而，尽管取得了很大进展，但任何国家都尚未实现流感疫苗接种的全部益处。
Objective: This report updates for 1996 and 1997 our 2 earlier reports on the use of influenza vaccination in various countries.Methods: Methods for obtaining information an influenza vaccine use from 1980 to 1995 in each country are described in our earlier reports. The current report includes data for 29 countries.Results: Among 16 countries of Western Europe, vaccine use increased substantially in The Netherlands, Finland (1996) and in Ireland (1997). In the remaining 13 countries, vaccine use increased somewhat or remained the same. In the US, vaccine use increased steadily throughout the 1990s, reaching a level of 281 doses per 1000 population in 1997. In New Zealand, there was a substantial increase in 1997, while vaccine use remained relatively unchanged in Canada, Australia and Korea. In Japan and Singapore, little or no influenza vaccine was used. In 1997, 6 countries in Central Europe used modest amounts of influenza vaccine. Among all 29 countries, in 1997 all but 3 (the UK, Ireland and Denmark) had age-based recommendations for influenza vaccination. This changed in 1998 when the UK and Denmark recommended vaccination for persons greater than or equal to 75 years and greater than or equal to 65 years of age, respectively. Ireland is considering an age-based recommendation. Many countries provide reimbursement for influenza vaccination through national or social health insurance, at least for some recommended groups. In virtually all countries, however, many persons pay for vaccination themselves. The levels of vaccine use in different countries are not related to per capita healthcare spending. Instead, they reflect different levels of awareness of influenza as an important disease and the effectiveness of vaccination in its prevention.Conclusions: Influenza Vaccination has continued to increase or has stabilised in most developed countries, and vaccine is also being used in several developing countries. In spite of much progress, however, the full benefits of influenza vaccination have yet to be achieved in any country.